GSK
Important news for Australian women with ovarian cancer will be announced Tuesday 18th January 2022 – with The Therapeutic Goods Administration (TGA) approving a new therapy – called Zejula also known as a PARP inhibitor – as a treatment option for newly diagnosed women with advanced ovarian cancer.
DETAILS:
- 4 Australian women are diagnosed with ovarian cancer every day in Australia, and due to the often late diagnosis and advanced nature of the cancer - 3 of these women will unfortunately die.
- Currently ovarian cancer's overall 5-year survival rate is almost half that of breast cancer.
- The Therapeutic Goods Administration (TGA) has now approved a new therapy – called Zejula also known as a PARP inhibitor – as a treatment option for newly diagnosed women with advanced ovarian cancer.
- Until now only women with a genetic mutation (BRCA gene – which Angelina Jolie created awareness of) could access this style of treatment.
- This new therapy may be given to women with advanced ovarian cancer regardless of whether they have a genetic mutation – which gives the 75% an new option to consider for their condition.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).
